This document discusses dry powder inhalation systems for the future, focusing on mometasone furoate delivered using Inhasphere technology. The Inhasphere system uses micronized anhydrous mometasone furoate powder that is over 75% encapsulated in microparticles with sizes around one micron to enable effective delivery to the lungs.